Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Articles|October 11, 2021
Daily OTC Pearl: Cetirizine (Zyrtec)
Author(s)Saro Arakelians, PharmD
Zyrtec is an antihistamine with principal effects mediated via selective inhibition of peripheral H1 receptors.
Advertisement
OTC/Lifestyle Pearl of the Day: Cetirizine (Zyrtec)
Indication: For relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis; symptoms of chronic idiopathic urticaria.
Insight:
- Dosing:
- Children from 2 to 6 years of age: 2.5 mg twice daily.
- Children from 6 to 12 years of age: 5 mg twice daily.
- Adolescents 12 years if age and above and adults: 10 mg once daily.
- Contraindication: Zyrtec is contraindicated during lactation. Hypersensitivity to any of the constituents of the formulation, to hydroxyzine, or to any piperazine derivatives.
- Adverse events include somnolence, fatigue, dizziness, and headache.
- Mechanism of action: Cetirizine, a human metabolite of hydroxyzine, is an antihistamine. Its principal effects are mediated via selective inhibition of peripheral H1 receptors.
- Manufacturer: Johnson and Johnson
Reference:
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5